Quantcast

Industry news that matters to you.  Learn more

Invivoscribe Receives FDA Approval for the LeukoStrat CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt and is the First Companion Diagnostic for AML

Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics® and personalized molecular medicine®, today announces the premarket approval of LeukoStrat® CDx FLT3 Mutation Assay. Due to current labeling for the FDA approved test, FLT3 mutation testing with LeukoStrat® CDx FLT3 Mutation Assay is exclusively performed by The Laboratory for Personalized Molecular Medicine, a subsidiary of Invivoscribe Technologies, Inc., which has gained FDA approval for its FLT3 test as a companion diagnostic for the Novartis drug Rydapt® in newly diagnosed FLT3+ AML.

Study Finds Biomarker for Lung Cancer Detection in the Nasal Passages of Smokers

A new nasal test may allow patients suspected of having lung cancer to undergo a simple swab of their nose to determine if they have the disease. Researchers at Boston University School of Medicine (BUSM) have found that a genomic biomarker in the nasal passage can accurately determine the likelihood of a lung lesion being malignant. The findings, which appear online in the Journal of the National Cancer Institute, will allow physicians to confidently identify patients who are at low probability for having lung cancer, thus sparing them from costly and risky procedures.

Two Migration Proteins Boost Predictive Value of Pancreatic Cancer Biomarker

Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic cancer to detect early stage disease, a research team from The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.

Novel Biomarker Predicts Treatment Response in Chronic Leukemia

A newly identified biomarker may predict treatment response in patients with chronic myelogenous leukemia (CML), according to a Northwestern Medicine study.

Biomarker Predicts Poor Prognosis in African-Americans with Triple-Negative Breast Cancer

Having high levels of a certain biomarker is linked to poor prognosis in African-American patients with triple-negative breast cancer, while the same biomarker doesn’t influence disease outcomes in white patients, according to a new study.